LG. Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. Am J Physiol Renal Physiol 294: F1257-F1263, 2008. First published March 19, 2008 doi:10.1152/ajprenal.00588.2007.-We recently reported that urinary excretion rates of angiotensinogen provide a specific index of the intrarenal renin-angiotensin system status in angiotensin II-dependent hypertensive rats. Angiotensinogen concentrations in mouse plasma are thought to be much lower than those in rat plasma; however, detailed information is deficient due to lack of direct quantitative measurements of rodent angiotensinogen. To elucidate this issue, we have developed a quantitative method for measurement of rodent angiotensinogen using a sandwich-type ELISA. The standard curve for mouse and rat angiotensinogen exhibited a high linearity at 0.16 -10 and 0.08 -5 ng/ml, respectively, with correlation coefficients Ͼ0.99. While plasma angiotensinogen concentrations of male high serum IgA (HIGA) mice (IgA nephritis model animals, 1,308 Ϯ 47 ng/ml; n ϭ 10) were lower than those of control BALB/c mice (1,620 Ϯ 384; n ϭ 12), urinary angiotensinogen concentrations of HIGA mice (14.6 Ϯ 1.5 ng/ml; n ϭ 34) were higher than those of BALB/c mice (4.6 Ϯ 0.1; n ϭ 2). In a similar manner, while plasma angiotensinogen concentrations of Zucker diabetic fatty (ZDF) obese rats (type 2 diabetic model animals, 1,789 Ϯ 50 ng/ml; n ϭ 5) were lower than those of control ZDF lean rats (2,296 Ϯ 47; n ϭ 5), urinary angiotensinogen concentrations of ZDF obese rats (88.2 Ϯ 11.4 ng/ml; n ϭ 15) were higher than those of ZDF lean rats (31.3 Ϯ 1.9; n ϭ 15). These data indicate that plasma and urinary angiotensinogen concentrations are less in mice than rats. However, these data suggest that urinary angiotensinogen levels are different from plasma angiotensinogen levels in rodents. The development of rodent angiotensinogen ELISA allows quantitative comparisons in mouse and rat angiotensinogen levels in models of hypertension and cardiovascular and kidney diseases.
enzyme-linked immunosorbent assay; renin-angiotensin system; plasma; urine; mouse; rat THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays an important role in blood pressure regulation and fluid and electrolyte homeostasis (27) . In recent years, the focus of interest on the RAS has shifted to a main emphasis on the role of the local/tissue RAS in specific tissues (9) . Emerging evidence demonstrates the importance of the tissue RAS in the brain (1), heart (8), adrenal glands (24) , vasculature (5, 10) , as well as the kidneys (17) . There is substantial evidence that the major fraction of ANG II present in renal tissues is generated locally from angiotensinogen delivered to the kidney as well as from angiotensinogen locally produced by proximal tubule cells (6, 11, 26, 31) . Renin secreted by the juxtaglomerular apparatus cells into the renal interstitium and vascular compartments also provides a pathway for the local generation of ANG I (25) . The ANGconverting enzyme is abundant in the rat kidney and is present in proximal and distal tubules, the collecting ducts, and renal endothelial cells (4) . ANG I delivered to the kidney can also be converted to ANG II (22) . Therefore, all of the components necessary to generate intrarenal ANG II are present along the nephron (17, 27) .
The presence of all the components of the RAS in the kidney provides great flexibility in regulating intrarenal levels of ANG II independent from circulating levels of ANG II (28) . Recently, we reported (13-15, 18, 21 ) that urinary excretion rates of angiotensinogen provide a specific index of intrarenal RAS status in ANG II-dependent hypertensive rats. However, in those studies (13-15, 18, 21) , angiotensinogen levels were measured by conversion assay. This conversion assay requires three steps. First, samples are incubated with and without exogenous renin. Then, ANG I concentrations in paired test tubes are measured by RIA. Finally, converted ANG I is calculated as the difference between paired ANG I concentrations. Therefore, this conversion assay needs time-consuming procedures (ϳ2 days), indirect measurements, radioisotopes, and purified renin that is expensive and unobtainable. The direct quantitative assessment of rodent angiotensinogen would be useful for measurements of plasma and urine samples. Angiotensinogen concentrations in mouse plasma have been reported (2, 3, 7, 23) to be much lower than those in rat plasma. However, detailed information is lacking due to the previous unavailability of direct quantitative measurements of rodent angiotensinogen. To elucidate these issues, we have developed a direct quantitative method to measure the plasma and urinary angiotensinogen of mice and rats using a microtiterplate-based sandwich-type ELISA. In contrast to the aforementioned conversion assay, the newly developed ELISA does not need time-consuming procedures (ϳ3 h), indirect measurements, radioisotopes, or purified renin. Moreover, with the use of this ELISA, plasma and urinary angiotensinogen levels were assessed in a couple of experimental animal models to investigate whether urinary angiotensinogen levels are controlled differently from plasma angiotensinogen levels in mice and rats.
MATERIALS AND METHODS
Sample collection. The experimental protocol was approved by the Animal Care and Use Committee of Tulane University. Male C57BL/6 mice, Wistar rats, Zucker diabetic fatty (ZDF) obese rats (type 2 diabetic model animals), and the corresponding control ZDF lean rats were purchased from Charles River Laboratories. Male high serum IgA (HIGA) mice (IgA nephritis model animals) and the corresponding control BALB/c mice were purchased from Japan SLC. Trunk blood samples were collected into centrifuge tubes with EDTA after animals were decapitated. Urine samples were collected into centrifuge tubes using metabolic cages. After a centrifugation, plasma and urine samples were transferred and stored at Ϫ20°C until assayed. Some kidneys were removed and dropped in zinc-saturated formalin for tissue fixation.
Antibody preparation. We raised two lines of polyclonal antibodies in rabbits against synthetic oligopeptides corresponding to the N terminus of rodent angiotensinogen (AA: 135-150) and to the C terminus of rodent angiotensinogen (AA: 405-420), respectively. Both antibodies were affinity purified.
Western blot. Western blot analysis was performed as described previously (12, 19, 29) using LI-COR Odyssey infrared imaging system.
Immunohistochemistry. Immunohistochemistry was performed as described previously (16, 20, 30) using Dako Autostainer robotic system.
Plate preparation. The ELISA plates were coated with the Nterminal antibody as the amount of 100 l/well in 100 mmol/l carbonate buffer (pH 9.5) at 4°C for overnight. The plates were washed with PBS and blocked with 200 l/well of 1% BSA in PBS containing 0.05% NaN 3 at 4°C for overnight. The plates were stored at 2-8°C until use.
Expression vectors. The full-length, except for the signal peptide (AA: 1-24), of the mouse angiotensinogen (AA: 25-477) gene (accession number: NM_007428) was amplified by PCR using a high fidelity Pfu DNA polymerase (Promega) with sense primer (5Ј-CCG CTC GAG gac cgc gta tac atc cac ccc-3Ј) and antisense primer (3Ј-AAG AAT GCG GCC GCc acc aca ctc tgg ggg tta ttc-5Ј) from the mouse liver cDNA library (Clontech). Then, this fragment was inserted into pGEX4T1 expression vectors (Promega) with six consecutive histidine residues (6-His) tag at the 5Ј-end by restriction enzymes of Xho I and Not I.
In a similar manner, the full-length, except for the signal peptide (AA: polymerase with sense primer (5Ј-CGG AAT TCg acc gcg tat aca tcc acc cc-3Ј) and antisense primer (3Ј-CCG CTC GAG cac cac att ttg ggg gtt atc c-5Ј) from the rat liver cDNA library (Clontech). Then, this fragment was inserted into pGEX4T1 expression vectors with glutathione S-transferase (GST) tag at the 5Ј-end by restriction enzymes of EcoR I and Xho I. Recombinant proteins. The recombinant constructs were transformed into a high-efficiency expression bacterial strain (Takara). Large-scale bacterial cultures were induced with isopropyl-beta-Dthiogalactopyranoside (Takara) and harvested for protein purification. 6-His-tagged proteins and GST-tagged proteins were purified using purification kits (Upstate) at native conditions.
Development of sandwich ELISA. Highly purified recombinant proteins of rodent angiotensinogen were used as the standards. One hundred microliters per well of standard samples of rodent angiotensinogen (0.16 -10 ng/ml for mouse angiotensinogen or 0.08 -5.0 ng/ml for rat angiotensinogen diluted in ELISA buffer), plasma (1:2,500 for mice and rats diluted in ELISA buffer), and urine (1:25 for mice and rats diluted in ELISA buffer) samples were added into each well of the plates and incubated at 37°C for 1 h. After the incubation, the plates were washed with a washing buffer (PBS containing Tween-20, 0.05%, pH 7.5) for a total of seven times. In the following step, the plates were incubated with the 100 l/well of the horseradish peroxidase-labeled C-terminal antibody (1:30 diluted in antibody solution) at 37°C for 30 min. After the incubation, the plates were washed with the washing buffer for a total of nine times. In the next steps, the plates were incubated with the 100 l/well of 3,3Ј,5,5Ј-tetramethylbenzidine solution under light-protected conditions at room temperature for 30 min. Finally, the plates were applied with the 100 l/well of sulfuric acid (0.5 mol/l) to stop the reaction. The absorbance values were measured at 450 nm.
Statistical analysis. Statistical analysis was performed using a one-way factorial ANOVA with post hoc Scheffé's F-test. All data are means Ϯ SE. P Ͻ 0.05 was considered significant.
RESULTS AND DISCUSSION
Developed antibodies. As illustrated in Fig. 1A , an equal amount (10 ng) of various recombinant proteins (lanes 1, 4, and 6: 6-His-tagged mouse angiotensinogen; lane 2: GST; and lanes 3, 5, and 7: GST-tagged rat angiotensinogen) was blotted on a nitrocellulose membrane and Western blot was done with 6-His antibody (lane 1), GST antibody (lanes 2 and 3) , rodent angiotensinogen N-terminal antibody (lanes 4 and 5) , or rodent angiotensinogen C-terminal antibody (lanes 6 and 7) . The 6-His antibody recognized 6-His-tagged recombinant mouse angiotensinogen at 48 kDa (lane 1). The GST antibody recognized recombinant GST at 25 kDa (lane 2) and GST-tagged recombinant rat angiotensinogen at 72 kDa (lane 3
. Calculated molecular sizes of 6-His-tag, GST-tag, recombinant mouse angiotensinogen, and recombinant rat angiotensinogen are 1, 25, 47, and 47 kDa, respectively. Therefore, both of developed antibodies recognized recombinant rodent (mouse and rat) angiotensinogen as expected.
To verify the specificity of the detective antibody, the specificity of the C-terminal antibody was further examined by Western blot and immunohistochemistry.
As illustrated in Fig. 1B , left, extracted protein from kidney of ZDF obese rat (25 g on lane 3), extracted protein from (14) , intrarenal angiotensinogen is glycosylated in vivo and the glycosylation may account for this small difference in the molecular size between intrarenal angiotensinogen in vivo and recombinant angiotensinogen. At the same time, the C-terminal antibody was preadsorbed with the synthetic oligopeptide corresponding to the C terminus of rodent angiotensinogen (AA: 405-420) for overnight, and the duplicated membrane was probed with the preadsorbed C-terminal antibody. As illustrated in Fig. 1B , right, the corresponding signals were completely eliminated or reduced to a large extent (lane 9 for ZDF obese rat, lane 10 for HIGA mice, and lane 11 for 6-His-tagged recombinant mouse angiotensinogen). These data assure the specificity of the C-terminal antibody.
Furthermore, as illustrated in Fig. 1C , left, immunohistochemistry demonstrated that angiotensinogen was predominantly localized in proximal tubular cells, especially in the luminal side in kidneys of HIGA mice, which is consistent with a previous work (14) in Sprague-Dawley rats. At the same time, the C-terminal antibody was preadsorbed with the synthetic oligopeptide corresponding to the C terminus of rodent angiotensinogen (AA: 405-420) for overnight, and the consecutive slide was stained with the preadsorbed C-terminal antibody. As illustrated in Fig. 1C , right, the corresponding signals were completely eliminated. These data also assure the specificity of the C-terminal antibody.
Plate stability. To address stability of plates, the N-terminal antibody-coated ELISA plates were incubated at 37°C for 1, 8, or 15 days. Then, different concentrations of standard samples of rodent angiotensinogen were applied on these plates and Fig. 3 . A-B: freeze and thaw test. One mouse plasma sample and one rat plasma sample were frozen and thawed 0, 1, 2, and 3 times, and plasma angiotensinogen concentrations were measured by the present ELISA system. Significant differences were not observed in mouse (A) and in rat (B). C-D: accelerated test. One mouse plasma sample and one rat plasma sample were incubated at 37°C for 0, 1, 3, and 7 days, and plasma angiotensinogen concentrations were measured by the present ELISA system. Significant differences were not observed in mouse (C) and in rat (D). To focus on the changes in freeze and thaw test (A-B) or the changes in accelerated test (C-D), the data were presented as the ratios to angiotensinogen concentrations without freeze and thaw (A-B) or the ratios to angiotensinogen concentrations without acceleration (C-D). Different known concentrations of standard samples of mouse angiotensinogen were added into mouse plasma samples or mouse urine samples, and the added angiotensinogen concentrations were calculated as the difference between angiotensinogen concentrations in samples with and without the added angiotensinogen. Similar procedures were also done in rat samples. Recovery rates were Ͼ94.3% for mouse plasma, Ͼ86.9% for mouse urine, Ͼ85.6% for rat plasma, and Ͼ85.6% for rat urine.
processed, and the absorbance values were obtained. As demonstrated in Fig. 2, A and B, each concentration of standard samples of mouse angiotensinogen (A; n ϭ 6) or of rat angiotensinogen (B; n ϭ 6) exhibited similar absorbance values beyond 15 days. These data clearly indicate that the N-terminal antibody-coated ELISA plates are stable at least for 15 days after antibody coating.
Standard curves. As shown in Fig. 2 , C and D, a corresponding standard curve exhibited a high linearity from 0.16 to 10 ng/ml for mouse angiotensinogen (C; n ϭ 6 in each concentration) and from 0.08 to 5 ng/ml for rat angiotensinogen (D; n ϭ 6 in each concentration), respectively. The correlation coefficient was Ͼ0.99.
Detection limit. The lowest sensitivity for this system was determined using the guidelines under the National Committee for Clinical Laboratory Standards Evaluation Protocols and was 0.03 ng/ml for mouse angiotensinogen and 0.01 ng/ml for rat angiotensinogen.
Addition and recovery test. Different known concentrations of standard samples of mouse angiotensinogen were added into mouse plasma samples or mouse urine samples, and the added angiotensinogen concentrations were calculated as the difference between angiotensinogen concentrations in samples with and without the added angiotensinogen. Similar procedures were also done in rat samples. As demonstrated in Table 1 , recovery rates were Ͼ94.3% for mouse plasma, Ͼ86.9% for mouse urine, Ͼ85.6% for rat plasma, and Ͼ85.6% for rat urine.
Sample stability. To address stability of samples, two tests were performed: one was a freeze and thaw test and the other was an accelerated test. In a freeze and thaw test, one mouse plasma sample and one rat plasma sample were frozen and thawed zero, one, two, and three times, and plasma angiotensinogen concentrations were measured by the present ELISA system. As described in Fig. 3, A (mouse) and B (rat), significant differences were not observed. In an accelerated test, one mouse plasma sample and one rat plasma sample were incubated at 37°C for 0, 1, 3, and 7 days and plasma angiotensinogen concentrations were measured by the present ELISA system. As shown in Fig. 3 , C (mouse) and D (rat), significant differences were not observed. These data clearly indicate that angiotensinogen in plasma samples is stable without any preservatives or proteinase inhibitors except EDTA.
Intra-assay test. Intra-assay tests were performed using three different concentrations of mouse plasma samples, mouse urine samples, rat plasma samples, and rat urine samples. As summarized in Table 2 , the percentages of the coefficient of variation among wells are from 3.1 to 10.0%.
Inter-assay test. Inter-assay tests were performed using three different concentrations of mouse plasma samples, mouse urine samples, rat plasma samples, and rat urine samples. As summarized in Table 3 , the percentages of the coefficient of variation among plates are from 7.7 to 16.8%. Intra-assay tests were performed using 3 different concentrations of mouse plasma samples, mouse urine samples, rat plasma samples, and rat urine samples. Percentages of the coefficient of variation (%CVs) among wells are from 3.1 to 10.0%. Inter-assay tests were performed using 3 different concentrations of mouse plasma samples, mouse urine samples, rat plasma samples, and rat urine samples. %CVs among plates are from 7.7 to 16.8%. To confirm the cross-reactivity with other proteins, several numbers of proteins (20 g/ml) were applied on the present ELISA system and processed. The cross-reactivity for other proteins in this ELISA system was negligible. In addition, downstream products of angiotensinogen (20 g/ml) were also applied on the present ELISA system. The cross-reactivity for angiotensin peptides in this ELISA system was also negligible.
Specificity. To confirm the cross-reactivity with other proteins, several numbers of proteins (20 g/ml) were applied on the present ELISA system and processed. As shown in Table 4 , the cross-reactivity for other proteins in this ELISA system was negligible. In addition, downstream products of angiotensinogen (20 g/ml) were also applied to the present ELISA system. As demonstrated in Table 4 , the cross-reactivity for ANG peptides in this ELISA system was also negligible.
Plasma and urinary angiotensinogen concentrations in mice and rats. As demonstrated in Fig. 4A , plasma angiotensinogen concentrations were significantly higher in Wistar rats (4,626 Ϯ 645 ng/ml; n ϭ 2) compared with C57BL/6 mice (1,216 Ϯ 101 ng/ml; n ϭ 7). As demonstrated in Fig. 4B , urinary angiotensinogen concentrations were also significantly higher in Wistar rats (65.4 Ϯ 30.2 ng/ml; n ϭ 2) compared with C57BL/6 mice (9.8 Ϯ 0.3 ng/ml; n ϭ 3). Angiotensinogen concentrations in mouse plasma are thought to be much lower than those in rat plasma (2, 3, 7, 23) . In agreement, the present data also indicate that plasma and urinary angiotensinogen concentrations in mice are lower that in rats. The plasma levels are about one-fourth while urinary levels are about one-seventh compared with values in rats.
Plasma and urinary angiotensinogen concentrations in IgA nephritis model mice. As demonstrated in Fig. 4C , plasma angiotensinogen concentrations of HIGA mice (1,308 Ϯ 47 ng/ml; n ϭ 10) were significantly lower than those of the corresponding control BALB/c mice (1,620 Ϯ 384 ng/ml; n ϭ 12). However, as demonstrated in Fig. 4D , urinary angiotensinogen concentrations of HIGA mice (14.6 Ϯ 1.5 ng/ml; Fig. 4 . A-B: plasma and urinary angiotensinogen concentrations in mice and rats. Plasma angiotensinogen concentrations were significantly higher in Wistar rats compared with C57BL/6 mice (A). Urinary angiotensinogen concentrations were also significantly higher in Wistar rats compared with C57BL/6 mice (B). C-D: plasma and urinary angiotensinogen concentrations in high serum IgA (HIGA) mice (IgA nephritis model). Plasma angiotensinogen concentrations of HIGA mice were significantly lower than those of the corresponding control BALB/c mice (C). However, urinary angiotensinogen concentrations of HIGA mice were significantly higher than those of BALB/c mice (D). E-F: plasma and urinary angiotensinogen concentrations in Zucker diabetic fatty (ZDF) obese rats (type 2 diabetic model). Plasma angiotensinogen concentrations of ZDF obese rats were significantly lower than those of the corresponding control ZDF lean rats (E). However, urinary angiotensinogen concentrations of ZDF obese rats were significantly higher than those of ZDF lean rats (E). n ϭ 34) were significantly higher than those of BALB/c mice (4.6 Ϯ 0.1 ng/ml; n ϭ 2).
Plasma and urinary angiotensinogen concentrations in type 2 diabetic model rats. As demonstrated in Fig. 4E , plasma angiotensinogen concentrations of ZDF obese rats (1,789 Ϯ 50 ng/ml; n ϭ 5) were significantly lower than those of the corresponding control ZDF lean rats (2,296 Ϯ 47 ng/ml; n ϭ 5). However, as demonstrated in Fig. 4F , urinary angiotensinogen concentrations of ZDF obese rats (88.2 Ϯ 11.4 ng/ml; n ϭ 15) were significantly higher than those of ZDF lean rats (31.3 Ϯ 1.9 ng/ml; n ϭ 15).
In conclusion, we have developed antibodies and a sensitive and specific quantification system for mouse and rat angiotensinogen using sandwich ELISA. The present data suggest that urinary angiotensinogen levels are controlled differently from plasma angiotensinogen levels in rodents. The development of rodent angiotensinogen ELISA allows quantitative comparisons in mouse and rat angiotensinogen levels in models of hypertension and cardiovascular and kidney diseases.
